Rebalix
Xtrackers · sheet of 10 September 2026
Xtrackers · sheet of 10 September 2026ETF sheet · official issuer and register data
Xtrackers Msci Usa Health Care UCITS ETF 1d
IE00BCHWNW54 · IE00BCHWNW54 · USD · domicile Ireland
Equity · United States · Health careSFDR art. 6 (inferred)
Index tracked: MSCI USA Health Care Net Total Return USD Index (USD)
- TER
- 0.12%+ trans. 0.01%
- Fund size
- 793 m EUR
- Tracking difference
- +0.14%3-year avg
- 🇮🇹 tax rate
- —white list not published
- Replication
- Physical
- Income
- Distributingsemi-annual
Launch 12 Sept 2017 · costs from the KID as of 2 Sept 2026 · 61 securities held · 8 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 4 Aug 2026
The fund is passively managed.
INVESTMENT OBJECTIVE:
The aim is for your investment to track the performance, before fees and expenses, of the MSCI USA Health Care index (index).
DESCRIPTION OF INDEX:
The index is based on the MSCI USA index (Parent index), which is designed to reflect the performance of large and medium sized companies representing 85% of the readily available shares in the United States of America. The index contains all of the constituents of the Parent index assigned to the “MSCI USA Health Care” classification.
INDEX…
Performance since series start (in euro) — base 100
12 Sept 2017 → 8 Sept 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +22.1% |
| 3 years | +20.6% |
| 5 years | +31.2% |
| 10 years | series too young |
| Since series start | +132.5% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 15.75% | 14.40% | 15.04% |
| Max drawdown | −11.21% | −17.68% | −17.68% |
| Sharpe | 1.07 | 0.37 | 0.15 |
| Sortino | 1.76 | 0.53 | 0.22 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · IE00BCHWNW54 · IE00BCHWNW541
RebalixIE00BCHWNW54 · IE00BCHWNW54 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +14.22% | +14.05% | +0.17% |
| 2024 | +2.31% | +2.18% | +0.13% |
| 2023 | +1.89% | +1.76% | +0.13% |
| 2022 | −3.03% | −3.14% | +0.11% |
| 2021 | +24.83% | +24.83% | +0.00% |
Distributions · per share, in USD
Frequency: semi-annual · last 12 months: 0.8097 USD (1.21% of NAV) · last ex-date 19 Aug 2026
| Year | Payments | Total (USD) | Dividend yield |
|---|---|---|---|
| 2026 | 2 | 0.8097 | — |
| 2025 | 2 | 0.7642 | +1.37% |
| 2024 | 2 | 0.7139 | +1.29% |
| 2023 | 2 | 0.6585 | +1.20% |
| 2022 | 2 | 0.8762 | +1.52% |
Dividend yield: the year’s distributions over the share value (NAV) at the start of the year.
Holdings
Portfolio as declared by the issuer · 2 Sept 2026 · 61 securities · top-10 weight = 59.8%
| Top holdings | Weight |
|---|---|
| 14.7% | |
| 10.4% | |
| 7.3% | |
| 5.9% | |
| 5.7% | |
| 3.8% | |
| 3.5% | |
| 3.0% | |
| 3.0% | |
| 2.6% |
Countries (% of fund)
Sectors (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
XUHC · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 19 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE00BCHWNW54
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00BCHWNW54
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · IE00BCHWNW54 · IE00BCHWNW542